BioCentury | Oct 30, 2020
Finance

Oct. 29 Quick Takes: Ultragenyx, Scholar Rock, Galecto, Citrine-Bioprojet, miRagen-Viridian, Elpis, CASI-BioInvent

...by year-end for liver fibrosis related to non-alcoholic steatohepatitis and myelofibrosis. Citrine gains China rights to Bioprojet...
...disease play Citrine Medicine licensed exclusive development and commercialization rights in China from French biopharma Bioprojet...
...to $83 million in milestones plus tiered royalties. BC Staff Ultragenyx Pharmaceutical Inc. Scholar Rock Holding Corp. Elpis Galecto Inc. Citrine Medicine Bioprojet miRagen CASI...
BioCentury | Aug 15, 2019
Company News

Harmony crosses finish line with Wakix for narcolepsy

...Biosciences LLC (Plymouth Meeting, Pa.) licensed exclusive U.S. rights to develop and commercialize Wakix from Bioprojet...
BioCentury | Oct 13, 2017
Financial News

Harmony raises $270M, licenses narcolepsy drug

...Harmony also obtained exclusive, U.S. rights to develop and commercialize pitolisant ( BF2.649 ) from Bioprojet...
...Next half, Harmony plans to submit an NDA to FDA for pitolisant to treat narcolepsy. Bioprojet...
...subsidiary of Paragon Biosciences LLC (Chicago, Ill.). Harmony Biosciences LLC , Plymouth Meeting, Pa. Elizabeth S. Eaton BF2.649 pitolisant Bioprojet Harmony...
BioCentury | Oct 6, 2017
Financial News

Harmony raises $270M, licenses narcolepsy drug

...Harmony also obtained exclusive, U.S. rights to develop and commercialize pitolisant ( BF2.649 ) from Bioprojet...
...Next half, Harmony intends to submit an NDA to FDA for pitolisant to treat narcolepsy. Bioprojet...
...no other candidates in its pipeline. Harmony is a subsidiary of Paragon Biosciences LLC. Elizabeth S. Eaton pitolisant Bioprojet Histamine...
BioCentury | Dec 7, 2015
Clinical News

Wakix pitolisant regulatory update

...EMA’s CHMP recommended approval of Wakix pitolisant from Bioprojet to treat narcolepsy with or without cataplexy...
...treat narcolepsy with or without cataplexy. The product is a histamine H3 receptor (HRH3) antagonist. Bioprojet Pharma S.a.r.l....
BioCentury | Feb 16, 2015
Product Development

The straight dopa

...to have high molecular weights or lipophilicity that can hinder uptake into the brain. Both Bioprojet...
...Pierre Fabre's Head of CNS Research Pierre Sokoloff said the doses of the Abbott and Bioprojet...
...Institutions Mentioned Abbott Laboratories (NYSE:ABT), Abbott Park, Ill. American College of Neuropsychopharmacology (ACNP), Brentwood, Tenn. Bioprojet...
BioCentury | Sep 30, 2013
Regulation

Wake-up call

...reported. The most advanced is the histamine H3 receptor antagonist pitolisant ( BF2.649 ) from Bioprojet Pharma S.a.r.l....
...February, and two more to treat EDS in patients with Parkinson's disease (PD) in April. Bioprojet...
...is scheduled for Dec. 10. Companies and Institutions Mentioned Aerial BioPharma LLC , Morrisville, N.C. Bioprojet Pharma S.a.r.l....
BioCentury | Jun 11, 2007
Clinical News

1-{3-[3- regulatory update

...to grant Orphan Drug designation 1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine hydrochloride, a histamine H3 receptor antagonist, to treat narcolepsy. Bioprojet...
Items per page:
1 - 8 of 8
BioCentury | Oct 30, 2020
Finance

Oct. 29 Quick Takes: Ultragenyx, Scholar Rock, Galecto, Citrine-Bioprojet, miRagen-Viridian, Elpis, CASI-BioInvent

...by year-end for liver fibrosis related to non-alcoholic steatohepatitis and myelofibrosis. Citrine gains China rights to Bioprojet...
...disease play Citrine Medicine licensed exclusive development and commercialization rights in China from French biopharma Bioprojet...
...to $83 million in milestones plus tiered royalties. BC Staff Ultragenyx Pharmaceutical Inc. Scholar Rock Holding Corp. Elpis Galecto Inc. Citrine Medicine Bioprojet miRagen CASI...
BioCentury | Aug 15, 2019
Company News

Harmony crosses finish line with Wakix for narcolepsy

...Biosciences LLC (Plymouth Meeting, Pa.) licensed exclusive U.S. rights to develop and commercialize Wakix from Bioprojet...
BioCentury | Oct 13, 2017
Financial News

Harmony raises $270M, licenses narcolepsy drug

...Harmony also obtained exclusive, U.S. rights to develop and commercialize pitolisant ( BF2.649 ) from Bioprojet...
...Next half, Harmony plans to submit an NDA to FDA for pitolisant to treat narcolepsy. Bioprojet...
...subsidiary of Paragon Biosciences LLC (Chicago, Ill.). Harmony Biosciences LLC , Plymouth Meeting, Pa. Elizabeth S. Eaton BF2.649 pitolisant Bioprojet Harmony...
BioCentury | Oct 6, 2017
Financial News

Harmony raises $270M, licenses narcolepsy drug

...Harmony also obtained exclusive, U.S. rights to develop and commercialize pitolisant ( BF2.649 ) from Bioprojet...
...Next half, Harmony intends to submit an NDA to FDA for pitolisant to treat narcolepsy. Bioprojet...
...no other candidates in its pipeline. Harmony is a subsidiary of Paragon Biosciences LLC. Elizabeth S. Eaton pitolisant Bioprojet Histamine...
BioCentury | Dec 7, 2015
Clinical News

Wakix pitolisant regulatory update

...EMA’s CHMP recommended approval of Wakix pitolisant from Bioprojet to treat narcolepsy with or without cataplexy...
...treat narcolepsy with or without cataplexy. The product is a histamine H3 receptor (HRH3) antagonist. Bioprojet Pharma S.a.r.l....
BioCentury | Feb 16, 2015
Product Development

The straight dopa

...to have high molecular weights or lipophilicity that can hinder uptake into the brain. Both Bioprojet...
...Pierre Fabre's Head of CNS Research Pierre Sokoloff said the doses of the Abbott and Bioprojet...
...Institutions Mentioned Abbott Laboratories (NYSE:ABT), Abbott Park, Ill. American College of Neuropsychopharmacology (ACNP), Brentwood, Tenn. Bioprojet...
BioCentury | Sep 30, 2013
Regulation

Wake-up call

...reported. The most advanced is the histamine H3 receptor antagonist pitolisant ( BF2.649 ) from Bioprojet Pharma S.a.r.l....
...February, and two more to treat EDS in patients with Parkinson's disease (PD) in April. Bioprojet...
...is scheduled for Dec. 10. Companies and Institutions Mentioned Aerial BioPharma LLC , Morrisville, N.C. Bioprojet Pharma S.a.r.l....
BioCentury | Jun 11, 2007
Clinical News

1-{3-[3- regulatory update

...to grant Orphan Drug designation 1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine hydrochloride, a histamine H3 receptor antagonist, to treat narcolepsy. Bioprojet...
Items per page:
1 - 8 of 8